NEW YORK (GenomeWeb News) - Gene Logic said today that it has signed a drug-repositioning agreement with Abbott that covers multiple clinical drug candidates that have passed Phase I human clinical trials.
 
Gene Logic said it stands to receive milestone payments for each new drug candidate that Abbott reenters into clinical development, as well as royalties for drug candidates that make it to market.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.